open access

Vol 4, No 2 (2003): Practical Diabetology
Original articles (submitted)
Published online: 2003-04-28
Get Citation

Application of gliclazide MR in uncontrolled diabetes type 2 — the treatment phase results of DINAMIC 2 study (V)

Jacek Sieradzki, Teresa Kasperska-Czyżyk, Władysław Grzeszczak oraz Zespół Badaczy DINAMIC
Diabetologia Praktyczna 2003;4(2):133-136.

open access

Vol 4, No 2 (2003): Practical Diabetology
Original articles (submitted)
Published online: 2003-04-28

Abstract

Tight glycemic control is universally acknowledged as a therapeutic priority in multifactorial management in type 2 diabetes [1, 2]. Achieving control to recommended targets, typically defined as Ł 7% or even Ł 6,5% glycated hemoglobin [1, 2], improves microvascular [3, 4] and possibly macrovascular [4] outcomes, but represents a considerable clinical challenge and carries resource implications. DINAMIC 2 study sampled populations of type 2 diabetic patients attending in primary care settings, in order to generate data about of glycemia [5]. Following this survey phase of the study other data, patients identified as having inadequate control were included into a 6 month trial of the efficacy and acceptability of once-daily sulfonylurea preparation, gliclazide modified release (Diamicron MR), alone or in combination with other oral antidiabetic agents.

Abstract

Tight glycemic control is universally acknowledged as a therapeutic priority in multifactorial management in type 2 diabetes [1, 2]. Achieving control to recommended targets, typically defined as Ł 7% or even Ł 6,5% glycated hemoglobin [1, 2], improves microvascular [3, 4] and possibly macrovascular [4] outcomes, but represents a considerable clinical challenge and carries resource implications. DINAMIC 2 study sampled populations of type 2 diabetic patients attending in primary care settings, in order to generate data about of glycemia [5]. Following this survey phase of the study other data, patients identified as having inadequate control were included into a 6 month trial of the efficacy and acceptability of once-daily sulfonylurea preparation, gliclazide modified release (Diamicron MR), alone or in combination with other oral antidiabetic agents.
Get Citation
About this article
Title

Application of gliclazide MR in uncontrolled diabetes type 2 — the treatment phase results of DINAMIC 2 study (V)

Journal

Clinical Diabetology

Issue

Vol 4, No 2 (2003): Practical Diabetology

Pages

133-136

Published online

2003-04-28

Bibliographic record

Diabetologia Praktyczna 2003;4(2):133-136.

Authors

Jacek Sieradzki
Teresa Kasperska-Czyżyk
Władysław Grzeszczak oraz Zespół Badaczy DINAMIC

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl